[go: up one dir, main page]

Cooper et al., 2022 - Google Patents

Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease

Cooper et al., 2022

View PDF
Document ID
5676042993970872947
Author
Cooper M
Zhang L
Ibrahim M
Zhang K
Sun X
Röske J
Göhl M
Brönstrup M
Cowell J
Sauerhering L
Becker S
Vangeel L
Jochmans D
Neyts J
Rox K
Marsh G
Maple H
Hilgenfeld R
Publication year
Publication venue
Journal of Medicinal Chemistry

External Links

Snippet

SARS-CoV-2 is the causative agent behind the COVID-19 pandemic. The main protease (Mpro, 3CLpro) of SARS-CoV-2 is a key enzyme that processes polyproteins translated from the viral RNA. Mpro is therefore an attractive target for the design of inhibitors that block viral …
Continue reading at pubs.acs.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Similar Documents

Publication Publication Date Title
Cooper et al. Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease
Cannalire et al. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities
Zhang et al. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment
Narayanan et al. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
Dai et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Gao et al. Perspectives on SARS-CoV-2 main protease inhibitors
Ma et al. Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors
TWI807291B (en) Compounds and methods for the treatment of covid-19
Calleja et al. Inhibitors of sars-cov-2 plpro
Cannalire et al. SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells
Hu et al. Enterovirus D68 antivirals: past, present, and future
Kim et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses
Brewitz et al. Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic cysteine
Ashhurst et al. Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L
Kumar et al. Anti-SARS coronavirus agents: a patent review (2008–present)
Huang et al. A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants
DeGoey et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A
Kohler et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors
WO2021205296A1 (en) Method of treating covid-19
Ghosh et al. Recent drug development and medicinal chemistry approaches for the treatment of SARS‐CoV‐2 infection and COVID‐19
Mukherjee et al. Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies
Yuan et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition
JP2021138694A (en) Methods of Inhibiting SARS-CoV-2 Replication and Treating Coronavirus Disease 2019
Malla et al. Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine
Feng et al. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein